Abstract
Due to the growing prevalence and morbidity of asthma in children in the past few years, Canadian physicians have addressed several issues concerning the correct use of beta2-agonists for the treatment of asthma. These issues include the optimum delivery systems for beta2-agonists, their appropriate dosages in children, infants and toddlers, and whether tachyphylaxis occurs with their chronic use.